Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous HBV-specific TCR-expressing T lymphocytes SCG101

A preparation of human autologous T lymphocytes transduced with a retroviral vector encoding for a T-cell receptor (TCR) specific for HLA-A*02-restricted human hepatitis B virus (HBV) surface antigen (HBsAg) peptide, with potential antineoplastic activity. Upon administration, the autologous HBV-specific TCR-expressing T lymphocytes SCG101 recognize and bind to HBV antigen-positive cells, which induces cytotoxic T-lymphocyte (CTL)-mediated elimination of HBV antigen-positive cells, including those in HBV-related hepatocellular carcinoma (HCC).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous HBV-specific T-cell receptor-expressing T lymphocytes SCG101
autologous HBV-specific TCR T cells SCG101
Code name:SCG 101
SCG-101
SCG101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search